Thailand Peptides
Get in Contact
Catalog
PeptidesCategories
Research
CompareInformation
Calculator
Get in Contact
Comparison · GLP-1 Metabolic

Semaglutide vs Tirzepatide

Semaglutide and Tirzepatide are the two most-studied GLP-1-class peptides. Semaglutide is a long-acting GLP-1 receptor agonist. Tirzepatide is a dual GIP/GLP-1 agonist. The head-to-head SURPASS-2 trial is the reason this comparison exists in the literature at all.

Bangkok research desk ·

Side-by-side

Semaglutide Tirzepatide
MechanismGLP-1 receptor agonist.Dual GIP and GLP-1 receptor agonist.
Half-life~7 days.~5 days.
Dose0.25-2.4 mg weekly SC (STEP titration).2.5-15 mg weekly SC (SURMOUNT titration).
CycleTitration: 4 weeks per step.Titration: 4 weeks per step.
Research contextSTEP-1 weight loss; SELECT cardiovascular outcomes1.SURMOUNT-1 weight loss; SURPASS-2 head-to-head vs Semaglutide2.
Cost tierMid-to-high.High.

Semaglutide and Tirzepatide are the two peptides researchers most often compare because SURPASS-2 put them directly head to head in T2DM. In that trial, Tirzepatide produced greater A1c reductions and greater weight loss than Semaglutide at the doses compared2. The SURMOUNT-1 weight-management data in non-diabetic participants showed similar relative advantage for Tirzepatide on weight endpoints3. Semaglutide's own dataset is anchored by STEP-1 (obesity without diabetes) and SELECT (cardiovascular outcomes in obesity)1.

The mechanism difference explains most of the data. Semaglutide agonises only GLP-1. Tirzepatide agonises GIP and GLP-1 at the same molecule. GIP adds a complementary incretin pathway that appears to amplify insulin sensitivity and energy expenditure, which in aggregate produces the greater clinical effect. Both drugs delay gastric emptying, drive satiety, and share the same GI-tolerability profile at comparable titration steps.

Titration is where most research-protocol errors happen. Both drugs require dose escalation over ~16 weeks: Semaglutide starts at 0.25 mg and climbs to 2.4 mg; Tirzepatide starts at 2.5 mg and climbs to 15 mg. Skipping steps drives GI-tolerability failure. See the GLP-1 titration protocols article for the full schedule walkthrough, and Semaglutide vs Tirzepatide trials for the trial-by-trial breakdown.

Frequently asked

Is Tirzepatide strictly better than Semaglutide?
On weight-loss endpoints at maximum approved doses, Tirzepatide produces greater mean reductions in the head-to-head and weight-management trials2. The choice between them in research still depends on endpoint, budget, and whether the GIP component is relevant to the question.
Do both require the same titration?
Both require ~16-week titration schedules with dose escalation every 4 weeks. Semaglutide climbs 0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg. Tirzepatide climbs 2.5 → 5.0 → 7.5 → 10.0 → 12.5 → 15.0 mg. Skipping steps causes GI intolerance.
Can they be combined?
No. Both agonise GLP-1, so combining them does not add a new mechanism and roughly doubles the side-effect profile. Researchers select one or the other.
Research desk
Ordering both Semaglutide and Tirzepatide for a research protocol? The Bangkok desk handles pricing, COA, and timing on WhatsApp.
Open a line with the research desk ≥98% HPLC purity · supplier COA on file · Bangkok-based

Go deeper

Related comparisons

References

  1. Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP-1). N Engl J Med. 2021. PMID: 33567185
  2. Frías JP, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). N Engl J Med. 2021. PMID: 34170647
  3. Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022. PMID: 35658024

All references verified against PubMed via NCBI E-utilities.